

Page # 41  
Article

FORM PTO-1449 (Modified)		Attorney Docket No.: 11823-002630US		Application No.: 08/484,537	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: QUEEN ET AL.			
		Filing Date: June 7, 1995		Group: 1642	
Reference Designation		<b>U.S. PATENT DOCUMENTS</b>			Page 1 of 2
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>					
	Document No.	Date	Country	Class	Translation (Yes/No)
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
gb	AA	Opposition to EP 0456216, Third Party Observations, May 25, 1998.			
	AB	Opposition to EP 0456216, Further Submissions of Medical Research Council, June 24, 1998.			
	AC	Opposition to EP 0456216, Summons to Attend Oral Proceedings, May 12, 1999.			
	AD	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., September 17, 1999.			
	AE	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., October 26, 1999.			
	AF	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., December 1, 1999.			
	AG	Opposition to EP 0456216, Further Third Party Observations, December 14, 1999.			
	AH	Opposition to EP 0456216, Further Submissions of Celltech Therapeutics, December 16, 1999.			
	AI	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Declaration of Thornton/Martin.			
	AJ	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: printouts from Protein Design Labs, Inc.'s website.			
	AK	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Tables showing derivatization of the antibody domains referred to in Fig. 3 / line 4 and Fig. 4F of WO 88/09344.			
	AL	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Schomburg, in <i>Advances in Protein Design</i> , Blöcker et al. (Eds.), 1989, pp. 45-56.			
	AM	Opposition to EP 0456216, Further Submissions of Genentech, Inc., December 17, 1999.			
	AN	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Verhoeven (including exhibits A, B and C).			
	AO	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Shak (including exhibits A, B and C).			
	AP	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Presta (including exhibits A and B).			
	AQ	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Reply of Protein Design Labs, Inc. in European patent application 92903551.7.			
	AR	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Letter of Dr. Seemann.			
	AS	Opposition to EP 0456216, Observations of Protein Design Labs, Inc., December 17, 1999.			
	AT	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of F. Vincenti (including exhibits 1 and 2).			
	AU	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. A. Scheinberg (including exhibits 1-4).			
EXAMINER		DATE CONSIDERED		4/28/00	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page #411  
Attach

FORM PTO-1449 (Modified)		Attorney Docket No.: 11823-002630US	Application No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: QUEEN ET AL.	
		Filing Date: June 7, 1995	Group: 1642
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
Page 2 of 2			
<input checked="" type="checkbox"/> AV	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Sung Co and Experimental report.		
<input type="checkbox"/> AW	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Nan Chang and Experimental report.		
<input type="checkbox"/> AX	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. D. Kornberg.		
<input type="checkbox"/> AY	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Levitt.		
<input type="checkbox"/> AZ	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of A. B. Edmundson.		
<input type="checkbox"/> BA	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Kirkman.		
<input type="checkbox"/> BB	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Junghans (including exhibits 1-6).		
<input type="checkbox"/> BC	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Vasquez.		
<input type="checkbox"/> BE <input checked="" type="checkbox"/> D	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. Panka.		
<input type="checkbox"/> BF <input checked="" type="checkbox"/> E	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. J. Poljak.		
<input type="checkbox"/> BG <input checked="" type="checkbox"/> F	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of J. S. Huston.		
<input type="checkbox"/> BH <input checked="" type="checkbox"/> G	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Queen and experimental report.		
<input type="checkbox"/> BI <input checked="" type="checkbox"/> H	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of N. Tsurushita and experimental report.		
<input type="checkbox"/> BJ <input checked="" type="checkbox"/> I	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of W. Smith.		
<input type="checkbox"/> BK <input checked="" type="checkbox"/> J	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Examiner's Reasons for Allowance for U.S. Patent No. 5,225,539.		
<input type="checkbox"/> BL <input checked="" type="checkbox"/> K	Opposition to EP 0456216, Further Submissions of Schering Corp., February 11, 2000.		
<input type="checkbox"/> BM <input checked="" type="checkbox"/> L	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 8, 2000.		
<input type="checkbox"/> BN <input checked="" type="checkbox"/> M	Opposition to EP 0456216, Attachment to Genentech's submissions of March 8, 2000: Declaration of Foote.		
<input type="checkbox"/> BO <input checked="" type="checkbox"/> N	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 13, 2000.		
<input type="checkbox"/> BP <input checked="" type="checkbox"/> O	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., March 16, 2000.		
<input checked="" type="checkbox"/> BQ <input checked="" type="checkbox"/> P	Opposition to EP 0456216, Minutes of Oral Proceedings issued by the EPO, April 5, 2000.		
EXAMINER	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
D33	<del>Winter patent (Medical Research Council) See AV</del> See Foreign Patent Documents		
D34	<del>Diamanstein application (Bayer Aktiengesellschaft) See AV</del> " " " "		
D35	QR	Verhoeven, BioEssays 8 (February/March 1988), 74-78	
D36	QR	Riechmann, Nature 332 (March 1988), 323-327	
D37	QR	Verhoeven, Science 239 (March 1988), 1534-1536	
D38	QR	Panka, Proc. Natl. Acad. Sci. USA 85 (May 1988) 3080-3084	
D39	QR	Davies, J. Biol. Chem., 263 (1988), 10541-10544	
D40	QR	Cheetham, Prot. Eng., 2 (September 1988) 170-172	
D41	QR	Matsumura, Nature, 334 (1988), 406-410	
D42	<del>Huston application (Creative Biomolecules) See AX</del> See Foreign Patent Documents		
D42'	<del>Huston (Creative Biomolecules) WO88/09344 (December 1, 1988), Fig. 3</del> . . . . .		
D43	<del>Huston application, See AX</del> See Foreign Patent Documents		
D44	<del>Comparison Chart for EP-A1 0 318 554 (Huston)</del> . . . . .		
D45	QR	Hale, The Lancet 2 (December 17, 1988), 1394-1399	
D46	<del>Bodmer application, (Celltech Limited), See AZ</del> See Foreign Patent Documents		
D47	<del>Hardman application, (Ciba-Geigy AG), See A1</del>		
D48	<del>Clark application (Medical Research Council), See A2</del>		
D49	<del>Queen application (Protein Design Labs), See A3</del>		
D50	<del>Hinton application (Becton Dickinson), See A4</del>		
D51	<del>Mezes application, (Dow Chemical) See A5</del>		
D52	QR	Queen, Proc. Natl. Acad. Sci., USA 86 (December 1989), 10029-10033	
D53	QR	Chothia, Nature, 342, (1989), 877-883	
D54	QR	Tramontano, J. Mol. Biol., 215 (1990), 175-182	
D55	<del>Queen Application (Protein Design Labs) See AA</del> See US Patent Documents		
D56	QR	Co, Proc. Natl. Acad. Sci., USA 88 (1991), 2869-2873	
D57	QR	Gorman, Proc. Natl. Acad. Sci., USA, 88 (1991), 4181-4185	
D58	QR	Routledge, Eur. J. Immunol., 21 (1991), 2717-2725	
D59	QR	Shearman, J. Immunol., 147 (1991), 4366-4373	
D60	QR	Kettleborough, Protein Engineering, 4, (1991), 773-783	
D61	QR	Tempest, Bio/Technology, 9, (1991), 266-271	

Julio (Rever, PLD)

B T2 99